Bright Minds Biosciences Stock Back In Retail’s Spotlight With $35M Funding Round Via Private Placement

Barchart · 10/18 08:16
Just two days prior, Bright Minds announced promising data from preclinical testing of BMB-201, a non-opioid alternative for neuropathic pain relief